Bielack, S S <br/><br/>
Rapid, complete and sustained tumour response to the TRK inhibitor larotrectinib in an infant with recurrent, chemotherapy-refractory infantile fibrosarcoma carrying the characteristic ETV6-NTRK3 gene fusion.  [electronic resource] 

 -  Annals of oncology : official journal of the European Society for Medical Oncology  11 2019 
 - viii31-viii35 p.  digital 
<br/><br/> Publication Type: Case Reports; Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1569-8041 
<br/><br/><label>Standard No.: </label>10.1093/annonc/mdz382  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Drug Resistance, Neoplasm<br/>Fibrosarcoma--drug therapy<br/>Humans<br/>Infant<br/>Infant, Newborn<br/>Male<br/>Neoplasm Recurrence, Local--drug therapy<br/>Oncogene Proteins, Fusion--genetics<br/>Protein Kinase Inhibitors--therapeutic use<br/>Pyrazoles--therapeutic use<br/>Pyrimidines--therapeutic use<br/>Salvage Therapy